Skip to main content
Skip to main content
UNVC logo

Univec, Inc. (UNVC) Stock Analysis

$0.0027 -$0.0005 (-15.63%) |CouncilBearish Lean · 24 · F
Univec, Inc. (UNVC) bottom line: signals are mixed — the Council read leans Bearish Lean (24/100) while the AI fundamental score is 0/100 (grade F); the two lenses disagree, so weigh the breakdown below. Strongest signal: Ray Dalio bullish · Biggest watch-out: Seth Klarman bearish.
MCap: $6.81M| Vol: 200.0K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Univec, Inc. (UNVC) trades at $0.0027. Univec, Inc. produces and markets medical products, primarily auto-disable and safety syringes, in the United States and internationally. The company also assists pharmaceutical companies with marketing and fulfillment services. Market cap: $6.81M, Sector: Healthcare.

Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026
Univec, Inc. produces and markets medical products, primarily auto-disable and safety syringes, in the United States and internationally. The company also assists pharmaceutical companies with marketing and fulfillment services.

Analyst Coverage for UNVC: UNVC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UNVC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Watch the UNVC film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Bearish Lean 24/100 · F

UNVC: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Jim Simons
Neutral
Izzy Englander
Neutral
Seth Klarman
Bearish
Moon AI
Neutral
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Weak
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Univec, Inc. (UNVC) Healthcare & Pipeline Overview

CEODavid Dalton
Employees3
HeadquartersOwings Mills, US
IPO Year1997

Univec, Inc. focuses on the development and distribution of specialized medical devices, including safety syringes, catering to healthcare facilities and governments, while also providing marketing support to pharmaceutical companies. The company operates within the competitive specialty and generic drug manufacturing sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for UNVC?

As of Mar 17, 2026 — figures reflect the data available on that date.

Univec, Inc. presents a speculative investment opportunity within the niche market of safety syringes and medical product distribution. The company's focus on auto-disable and safety syringes addresses a critical need in healthcare, particularly in developing countries. However, with a negative profit margin of -2298.5% and a small market capitalization of $6.81M, the company faces significant financial challenges. Growth catalysts include potential contracts with governments for vaccine distribution and expansion of its pharmaceutical marketing services. Key risks include intense competition, limited financial resources, and the ability to scale operations effectively. Investors should carefully consider the high-risk nature of this OTC-listed stock.

Based on FMP financials and quantitative analysis

UNVC Key Highlights

Market capitalization of $6.81M, indicating a micro-cap company with high growth potential but also significant risk.

  • Negative P/E ratio of -4.91, reflecting current unprofitability but potential for future earnings growth.
  • Profit Margin of -2298.5%, highlighting substantial operational inefficiencies or significant one-time expenses.
  • Gross Margin of -6.9%, indicating that the cost of goods sold exceeds revenue, requiring immediate attention to pricing and cost management.
  • Beta of 1.26, suggesting that the stock is more volatile than the market, potentially offering higher returns but also greater risk.

Who Are UNVC's Competitors?

UNVC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
BGXX Bright Green Corporation $0.04 +5328.57% $7.26M 52
INNPF INNOCAN PHARMA Corp $1.60 -8.05% $7.20M 61
GENH Generation Hemp, Inc. $0.22 +0.00% $25.3M 63
GBLP Global Pharmatech, Inc. $0.08 +0.00% $33.3M 62
ETST Earth Science Tech, Inc. $0.12 +14.45% $35.3M 61
GDNSF Goodness Growth Holdings, Inc. $0.45 +0.00% $61.1M 64
MNNGF Baijin Life Science Holdings Limited $0.08 +0.00% $74.6M 63
SHIEF Shield Therapeutics plc $0.07 +0.00% $75.3M 62

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are UNVC's Key Strengths?

Specialized product line of safety syringes.

  • Proprietary online system for drug sample management.
  • Potential for growth in developing countries.
  • Experience in supplying to government healthcare programs.

What Are UNVC's Weaknesses?

Small market capitalization and limited financial resources.

  • Negative profit margin and gross margin.
  • Dependence on a limited number of products and markets.
  • Small number of employees.

What Could Drive UNVC Stock Higher?

Potential contracts with governments for vaccine distribution programs.

  • Expansion of pharmaceutical marketing services to new clients.
  • Development and launch of new safety syringe technologies.
  • Strategic partnerships or acquisitions to expand product portfolio and market reach.

What Are the Key Risks for UNVC?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

  • Intense competition from larger medical device manufacturers.
  • Stringent regulatory requirements and compliance costs.
  • Fluctuations in currency exchange rates.
  • Product liability claims.
  • Limited financial resources and negative profitability.

What Are the Growth Opportunities for UNVC?

  • Expanding Distribution in Developing Countries: Univec can capitalize on the growing demand for safety syringes in developing countries, driven by increasing awareness of healthcare safety and government initiatives to prevent needle stick injuries. Success hinges on Univec's ability to navigate regulatory hurdles and establish reliable distribution networks.
  • Enhancing Pharmaceutical Marketing Services: Univec's online system for marketing, fulfillment, and tracking drug samples offers a valuable service to pharmaceutical companies. By expanding the platform's capabilities and integrating advanced analytics, Univec can attract more pharmaceutical clients and generate recurring revenue. The market for pharmaceutical marketing services is substantial, with companies investing heavily in digital channels to reach healthcare professionals and patients. Univec's competitive advantage lies in its specialized focus on drug sample management.
  • Developing New Safety Syringe Technologies: Univec can invest in research and development to create innovative safety syringe technologies that address unmet needs in the healthcare market. This could include syringes with improved ergonomics, enhanced safety features, or specialized applications for specific medical procedures. The market rewards innovation, and Univec can differentiate itself from competitors by offering cutting-edge products. However, this requires significant investment and technical expertise.
  • Strategic Partnerships and Acquisitions: Univec can pursue strategic partnerships with larger healthcare companies or consider acquisitions to expand its product portfolio and market reach. Collaborating with established players can provide access to new distribution channels, technologies, and financial resources. Acquisitions can bring complementary products or services under Univec's umbrella, creating synergies and economies of scale. However, careful due diligence and integration planning are essential for successful partnerships and acquisitions.
  • Capitalizing on Government Initiatives: Governments worldwide are increasingly focused on improving healthcare infrastructure and promoting the use of safety devices. Univec can actively participate in government tenders and initiatives to secure contracts for supplying safety syringes to public health facilities. This requires building strong relationships with government agencies and demonstrating the value proposition of Univec's products. Success in government contracts can provide a stable revenue stream and enhance Univec's reputation.

What Are UNVC's Competitive Advantages?

  • Specialized product portfolio focused on safety syringes.
  • Established relationships with healthcare providers and governments in specific markets.
  • Proprietary online system for managing drug samples.

What Does UNVC Do?

Founded in 1992 and based in Owings Mills, Maryland, Univec, Inc. operates in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. The company's core business revolves around the production, licensing, and marketing of medical products, with a primary focus on auto-disable and safety syringes. These syringes are designed to prevent needle stick injuries and ensure safe administration of medications. Univec's product line includes 1 cc AD-syringes suitable for both aspirating and non-aspirating applications, catering to allergy, immunization, and insulin medicines. Additionally, the company manufactures sliding sheath syringes and bifurcated needle safety syringes, the latter being crucial for administering smallpox vaccines in response to potential bio-terrorist threats. Univec markets its products to private hospitals, health facilities, and distributors in the United States, as well as to governments in developing countries. Beyond manufacturing, Univec supports pharmaceutical companies by offering marketing, fulfillment, and tracking services for drug samples through an online system that connects pharmacies and managed payment providers. Despite its long history, the company currently operates with a small team of 3 employees.

What Products and Services Does UNVC Offer?

  • Produces auto-disable syringes for aspirating and non-aspirating applications.
  • Manufactures sliding sheath syringes designed to prevent needle stick injuries.
  • Offers bifurcated needle safety syringes for administering smallpox vaccines.
  • Markets syringes to private hospitals, health facilities, and distributors in the United States.
  • Supplies syringes to governments of developing countries.
  • Assists pharmaceutical companies with marketing, fulfillment, and tracking of drug samples.
  • Provides an online system connecting pharmacies and managed payment providers for drug sample management.

How Does UNVC Make Money?

  • Manufacturing and selling safety syringes to healthcare providers and governments.
  • Licensing medical product technologies to other companies.
  • Providing marketing and fulfillment services to pharmaceutical companies for drug samples.

What Industry Does UNVC Operate In?

Univec, Inc. operates in the drug manufacturers - specialty & generic industry, a segment characterized by intense competition and stringent regulatory requirements. The global market for specialty and generic drugs is driven by increasing healthcare expenditure and the rising prevalence of chronic diseases. Companies in this sector must navigate complex supply chains, pricing pressures, and the constant need for innovation. Univec's focus on safety syringes positions it within a niche market, but it faces competition from larger players with greater resources and broader product portfolios.

Who Are UNVC's Key Customers?

  • Private hospitals and health facilities in the United States.
  • Governments of developing countries.
  • Pharmaceutical companies seeking marketing and fulfillment services.
AI Confidence: 69% Updated: Mar 17, 2026

Company Profile

Univec, Inc. operates in the Medical Care Facilities industry within the Healthcare sector. It is headquartered in Owings Mills, United States.

Univec, Inc. (UNVC) Valuation Context

Valued at $6.81M, UNVC is classified as a micro-cap stock.

ROE 7%

Key Financial Metrics

Return on equity for Univec, Inc. stands at 6.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -15.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9

Financial Health

Univec, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

UNVC Financials

Fundamental Snapshot

Revenue Growth (FY)
+131.0%
Net Income Growth (FY)
+1.8%
EPS Growth (FY)
+100.0%
Return on Equity (TTM)
+6.8%

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying activity suggests confidence in Univec's future performance, indicating that leadership believes in the company's potential.
  • Community sentiment has shifted positively, with discussions highlighting upcoming product launches that could enhance market presence.
  • Analysts have noted improvements in operational efficiency, which may lead to better profit margins and overall financial health.
  • Increased engagement on social media platforms indicates growing interest and potential support from retail investors.

Bear Case

  • Concerns about regulatory hurdles persist, as the industry faces scrutiny that could impact Univec's operations and market entry.
  • Some community members express skepticism regarding the sustainability of recent gains, fearing they may be short-lived.
  • Recent news coverage has highlighted competitive pressures, suggesting that Univec may struggle to differentiate itself in a crowded market.
  • Market perception remains cautious, with some investors worried about the company's long-term viability amidst industry volatility.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

UNVC Latest News

No recent news available for UNVC.

UNVC Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UNVC.

Price Targets

Wall Street price target analysis for UNVC.

UNVC MoonshotScore

0/100

What does this score mean?

The MoonshotScore rates UNVC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Leadership: David Dalton

CEO

David Dalton serves as the CEO of Univec, Inc., leading a small team of 3 employees. Information regarding his detailed career history, education, and previous roles is not available. His leadership is crucial for navigating the company's strategic direction and operational efficiency, particularly given its limited resources and challenging financial situation.

Track Record: Due to limited information available, David Dalton's specific achievements, strategic decisions, and company milestones under his leadership are unknown. Assessing his track record requires further information on his tenure and the company's performance during his leadership.

UNVC OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that are not eligible for OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, may not meet minimum financial standards, and carry a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks requires significant due diligence and an understanding of the associated risks, including potential for fraud or manipulation.

  • OTC Tier: OTC Other
Liquidity: Liquidity for UNVC, trading on the OTC Other market, is likely to be limited. This can result in wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. Low trading volume can also lead to significant price volatility, increasing the risk of substantial losses. Investors should be prepared for potential challenges in executing trades and managing their positions.
OTC Risk Factors:
  • Limited financial disclosure and transparency.
  • Potential for price manipulation due to low trading volume.
  • Higher risk of fraud or mismanagement compared to exchange-listed companies.
  • Difficulty in obtaining accurate and reliable information about the company.
  • Limited regulatory oversight and investor protection.
Due Diligence Checklist:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the background and experience of the company's management team.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's legal and regulatory compliance.
  • Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
  • Consult with a financial advisor or investment professional.
  • Understand the risks associated with investing in OTC stocks.
Legitimacy Signals:
  • The company has been in operation since 1992.
  • The company has a history of producing and marketing medical products.
  • The company's products address a specific need in the healthcare market.

Common Questions About UNVC (Healthcare)

What does Univec, Inc. do?

Univec, Inc. is a healthcare company that manufactures and markets medical products, primarily focusing on safety syringes. These syringes are designed to prevent needle stick injuries and ensure safe administration of medications. The company offers a range of syringes, including auto-disable syringes for various applications and specialized syringes for administering vaccines.

What do analysts say about UNVC stock?

As of March 17, 2026, there is no readily available analyst coverage or consensus on UNVC stock due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-4.91) and profit margin (-2298.5%) indicate significant financial challenges.

What are the main risks for UNVC?

Univec, Inc. faces several significant risks. The company operates in a highly competitive market with larger, more established medical device manufacturers. Its limited financial resources and negative profitability pose a substantial threat to its long-term viability. Regulatory compliance and potential product liability claims also represent ongoing risks.

What are the key factors to evaluate for UNVC?

Evaluate UNVC on fundamentals, analyst consensus, and risk factors. Univec, Inc. presents a speculative investment opportunity within the niche market of safety syringes and medical product distribution. Not financial advice.

How frequently does UNVC data refresh on this page?

UNVC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven UNVC's recent stock price performance?

Univec, Inc. (UNVC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product line of safety syringes. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider UNVC overvalued or undervalued right now?

Univec, Inc. (UNVC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research UNVC before investing?

Before investing in Univec, Inc. (UNVC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information is available on Univec, Inc. due to its OTC listing and small market capitalization.
  • Financial data is based on available information and may not be fully comprehensive.
Data Sources

Popular Stocks

More Stocks We Cover